Eisai: Our Brief History
The History of Eisai: From a small R&D lab with 15 researchers to a global business in the top in pharma worldwide.
Toyoji Naito funded Sakuragaoka Laboratory, Ltd. in Japan
Nihon Eisai Co., Ltd., Eisai Co., Ltd.’s immediate predecessor was founded in Japan
Sakuragaoka Laboratory Co., Ltd. and Nihon Eisai Co., Ltd. merged under the name Nihon Eisai Co., Ltd.
The company changes its name from Nihon Eisai Co., Ltd. to Eisai Co., Ltd., as it is known today.
European operations established
Eisai establishes its UK R&D operation, Eisai London Research Laboratories, at University College London
Eisai introduces the corporate philosophy of hhc (human health care)
Aricept® (donepezil hydrochloride) was launched in part of Europe for the treatment of Alzheimer’s disease
COMMERCIAL OPERATIONS START IN SPAIN
European Regional HQ was established in London, UK
Eisai started marketing Zonegran® (zonisamide) in part of Europe for the adjunctive treatment of partial-onset seizures in adults
Plans announced for a Strategic European Base in UK
Commercial operations start in Portugal
Inovelon® (rufinamide) is launched in part of Europe, for the treatment of seizures associated with Lennox-Gastaut Syndrome (LGS)
European Knowledge Centre opened in Hatfield, UK as hub of European operations
Zebinix® (eslicarbazepine acetate) launched in part of Europe for the adjunctive treatment of partial-onset seizures in adults
Halaven® (eribulin mesylate) is launched in Europe
Antiepileptic agent Fycompa® (perampanel) is launched in Europe.
Eisai signs the London Declaration, which is committed to the elimination of ten neglected tropical diseases by 2020.
Anticancer agent Lenvima® (lenvatinib) is launched in part of Europe.
Eisai initiates free of charge provision of Diethylcarbamazine citrate tablets for use in National Lymphatic Filariasis Elimination Campaign in Indonesia.
Eisai joined in Access Accelerated, a global partnership to advance access to non-communicable diseases (NCDs) prevention, treatment and care in low and lower-middle income countries
Extension of the global collaboration agreement with Biogen to reserach, develop and commercialize treatments against Alzheimer’s disease
To learn more about Eisai’s history, please visit